Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Apr;32(4):589–591. doi: 10.1128/aac.32.4.589

Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus.

J Portnoy 1, R Hicks 1, F Pacheco 1, L Olson 1
PMCID: PMC172227  PMID: 3377468

Abstract

Eleven children with bronchiolitis induced by respiratory syncytial virus received 10,000 to 70,000 U of recombinant interferon alpha-2a per kg of body weight per day. None developed signs of toxicity, and all but one developed an antiviral state following treatment. Interferon alpha-2a appears to be safe for infants with bronchiolitis. Its efficacy for the treatment of this condition remains to be determined.

Full text

PDF
589

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dunnick J. K., Galasso G. J. From the National Institute of Allergy and Infectious Diseases. Update on clinical trials with exogenous interferon. J Infect Dis. 1980 Aug;142(2):293–299. doi: 10.1093/infdis/142.2.293. [DOI] [PubMed] [Google Scholar]
  2. Gresser I., Tovey M. G., Bandu M. E., Maury C., Brouty-Boyé D. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection. J Exp Med. 1976 Nov 2;144(5):1305–1315. doi: 10.1084/jem.144.5.1305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hall C. B., Douglas R. G., Jr, Simons R. L., Geiman J. M. Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections. J Pediatr. 1978 Jul;93(1):28–32. doi: 10.1016/s0022-3476(78)80594-0. [DOI] [PubMed] [Google Scholar]
  4. Levin S., Hahn T. Evaluation of the human interferon system in viral disease. Clin Exp Immunol. 1981 Dec;46(3):475–483. [PMC free article] [PubMed] [Google Scholar]
  5. Levin S., Hahn T. Interferon deficiency syndrome. Clin Exp Immunol. 1985 May;60(2):267–273. [PMC free article] [PubMed] [Google Scholar]
  6. Levin S. Interferon in acute viral infections. Eur J Pediatr. 1983 Mar;140(1):2–4. doi: 10.1007/BF00661894. [DOI] [PubMed] [Google Scholar]
  7. McIntosh K. Interferon in nasal secretions from infants with viral respiratory tract infections. J Pediatr. 1978 Jul;93(1):33–36. doi: 10.1016/s0022-3476(78)80595-2. [DOI] [PubMed] [Google Scholar]
  8. Parrott R. H., Kim H. W., Brandt C. D., Chanock R. M. Respiratory syncytial virus in infants and children. Prev Med. 1974 Dec;3(4):473–480. doi: 10.1016/0091-7435(74)90010-3. [DOI] [PubMed] [Google Scholar]
  9. Rubinstein S., Familletti P. C., Pestka S. Convenient assay for interferons. J Virol. 1981 Feb;37(2):755–758. doi: 10.1128/jvi.37.2.755-758.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Scott G. M., Secher D. S., Flowers D., Bate J., Cantell K., Tyrrell D. A. Toxicity of interferon. Br Med J (Clin Res Ed) 1981 Apr 25;282(6273):1345–1348. doi: 10.1136/bmj.282.6273.1345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Trown P. W., Kramer M. J., Dennin R. A., Jr, Connell E. V., Palleroni A. V., Quesada J., Gutterman J. U. Antibodies to human leucocyte interferons in cancer patients. Lancet. 1983 Jan 15;1(8316):81–84. doi: 10.1016/s0140-6736(83)91737-3. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES